NEWSPACE-CAPITAL
15.12.2022 08:31:42 CET | Business Wire | Press release
NewSpace Capital announces the first closing of its space-focused growth fund at €105M and a €15M lead investment in Cailabs’ series C investment round.
NewSpace Capital is a Luxembourg-based private equity fund dedicated to space-focused technology investments. The firm targets growth-equity opportunities in downstream applications and supply chain segments of the space market. NewSpace Capital has a global investment outlook with its main focus on Europe and the US. The closing was led by a cornerstone investment from Archean Capital Partners, a US fund dedicated to investing in emerging fund managers with specialized sector and operational experience. Other investors include corporates, financial institutions and family offices.
NewSpace Capital is also announcing a €15M investment in Cailabs, a French deep-tech company enabling revolutionary photonic solutions for industrial and communication applications. NewSpace Capital is the lead investor in Cailabs’ €26M series C financing round.
The fund’s other investments to date include ICEYE, which owns and operates the world’s largest constellation of synthetic aperture radar (SAR) satellites, and Kayrros, a climate-tech data analytics company that recently won the Financial Times’ prestigious 2022 Tech Champions Award.
Rob Lazaroff, Co-Portfolio Manager of Archean Capital said, “There are an increasing number of companies reaching the commercial stage in space, many of which are ready for growth stage capital. The NewSpace Capital team has an ideal mix of technical and commercial expertise to identify and select the best space companies, and help them achieve their growth plans.”
“We are very selective in backing new funds and we are willing to wait for the right combination of team, strategy and market opportunity. NewSpace Capital has an amazing network within the space ecosystem that makes them a preferred partner to companies like Cailabs. We are thrilled to support the team as they build NewSpace Capital into the next market leading private equity firm” said Chris Keller, Co-Portfolio Manager of Archean Capital.
“The space ecosystem becomes a backbone for economic and social change. We are a value investor in companies that enable this process with new technologies and capabilities. NewSpace Capital allows its LPs to tap into the growth segment of a €300-billion industry spanning Earth observation, communication and data analytics. We are excited to partner with Archean, whose team brings a wealth of knowledge and a unique partnership approach” said Bogdan Gogulan, CEO and Managing Partner of NewSpace Capital.
NewSpace Capital is a conduit to enable corporates and financial investors to achieve net-zero targets: “The space industry is critical to solving global ESG challenges. In addition to identifying, measuring, and mitigating the environmental impact of existent economic activity that can be done from space on a global scale, space infrastructure and space-enabled services also create a completely new way of operating for traditional industries, that allows the transition to a more efficient and net-zero economy,” said Felix von Schubert, Executive Chairman of NewSpace Capital.
About NewSpace Capital
NewSpace Capital is a global space-focused, growth-stage fund operated by a team that together has more than 150 years of investment, commercial and technical experience in the space and private equity industries. Based in Luxembourg, the fund provides growth capital to companies with a technological edge and leading market position in the supply chain and applications segments of the rapidly developing space ecosystem. To learn more visit www.newspace.capital
About Archean Capital Partners
Archean Capital Partners provides strategic anchor capital to newly-formed private equity firms. Archean was established in 2017 by Veritable, L.P. and Moelis Asset Management to provide initial limited partner capital and value-added support to highly qualified emerging managers. Archean is focused on opportunities in such specialties as buyout, growth, restructuring and turnaround. To learn more visit www.archeancapital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom